Predictors of glycemic control in the first year of diagnosis of childhood onset type 1 diabetes: A systematic review of quantitative evidence by Paes, Veena Mazarello et al.
 Running title Page 
 
Short running title: Predictors of early HbA1c in childhood onset T1D.   
 
Corresponding author:  
Veena Mazarello Paes 
UCL Great Ormond Street Institute of Child Health,  
1st floor, Wellcome Trust Building, 
30 Guilford Street 
London WC1N 1EH 
UK 
Tel: +44 (0)20 7905 2805 
Email: veena.paes.14@ucl.ac.uk  
 
 
  
 Title Page 
 
Predictors of glycemic control in the first year of diagnosis of childhood onset type 1 diabetes: A systematic review of 
quantitative evidence.  
Veena Mazarello Paes1, 2, Dimitrios Charalampopoulos1, Julie Edge3, David Taylor-Robinson1, 4, Terence Stephenson1, Rakesh 
Amin1 
 
1Great Ormond Street Institute of Child Health, University College London, UK 
2University of Cambridge, UK 
3University of Oxford, UK 
4University of Liverpool, UK 
 
Authors details: 
1. Veena Mazarello Paes MSc, MPH, MPhil, PhD cand. 
Children’s Policy Research Unit, 
UCL Great Ormond Street Institute of Child Health, 
London WC1N 1EH,  
UK 
Department of Paediatrics, 
University of Cambridge, 
Cambridge, UK 
 
2. Dimitrios Charalampopoulos MD, MPhil 
Children’s Policy Research Unit, 
UCL Great Ormond Street Institute of Child Health, 
London WC1N 1EH,  
UK 
 
3. Julie A. Edge MD, FRCPCH 
University of Oxford,  
Oxford OX3 9DZ 
UK 
 
4. David Taylor-Robinson PhD 
Department of Public Health and Policy 
University of Liverpool, 
Liverpool L69 3BX 
UK 
 
5. Terence Stephenson DM, FRCPCH 
Children’s Policy Research Unit, 
 UCL Great Ormond Street Institute of Child Health, 
London WC1N 1EH,  
UK 
 
6. Rakesh Amin MBChB (Hons), FRCP 
Children’s Policy Research Unit, 
UCL Great Ormond Street Institute of Child Health, 
London WC1N 1EH,  
UK 
Word count: abstract: 232 and main text (excluding references): 3161 
  
 Abstract and key word page 
 
Predictors of glycemic control in the first year of diagnosis of childhood onset type 1 diabetes: A systematic review of 
quantitative evidence.  
Veena Mazarello Paes1, 2, Dimitrios Charalampopoulos1, Julie Edge3, David Taylor-Robinson1, 4, Terence Stephenson1, Rakesh 
Amin1 
 
1Great Ormond Street Institute of Child Health, University College London, UK 
2University of Cambridge, UK 
3Oxford Children’s Hospital, University of Oxford, UK 
4University of Liverpool, UK  
 
ABSTRACT 
 
Background: Early glycemic control is associated with reduced future vascular complications risk in type 1 diabetes (T1D).  
 
Objective: To systematically review evidence on the predictors of glycemic control within 12 months of diagnosis of childhood onset 
T1D. 
 
Study design: Inclusion criteria for the electronic search were: interventional and observational studies that assessed and quantified 
an association between the predictor and glycemic control within 12 months of diagnosis of childhood onset T1D. 17,915 articles 
were identified from six databases and 20 studies were finally included in the analysis. Harvest plots and narrative synthesis were 
used to summarize data from intervention (n=0), prospective/retrospective cohort (n=15) and cross-sectional (n=5) studies.  
 
Results: Significant predictors of poorer glycemic control 0-3 months after diagnosis were older age and female gender. Non-white 
ethnicity, diabetes autoantibody positivity, measures of deprivation and non-private health insurance were potential predictors. 
Predictors of poorer glycemic control 4 to 12 months after diagnosis were: older age, non-white ethnicity, a single parent family, high 
HbA1c levels at diagnosis, longer T1D duration and non-intensive insulin therapy. Potential predictors included: family with health 
issues, clinic factors and co-morbidities at diagnosis.  
 
Conclusions: Most  significant  predictors of poor glycemic control within twelve months of diagnosis of childhood onset T1D are 
non-modifiable. These factors need to be recognized and addressed through individualized and multidisciplinary diabetes care. 
Further research is required to confirm the association of potential predictors with early glycemic control.  
  
PROSPERO registration: CRD42015024546 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024546 
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 INTRODUCTION 
 
Poor glycemic control in the first months following the diagnosis in childhood onset Type 1 Diabetes (T1D) tracks in subsequent years 
(1-4) and is associated with elevated risk of vascular complications in later life (5-11). However, achieving target blood glucose and 
HbA1c levels during the first few appointments in pediatric diabetes clinics remains a challenge and is not always the focus of 
discussions with family members (12-14).  
   
Recent systematic reviews have shown that achieving lower HbA1c levels at early stages of the disease through use of intensive 
insulin therapies in adult T1D patients was beneficial in reducing subsequent vascular complications risk and mortality (15, 16). But 
these associations and other factors influencing early glycemic control have not been clearly reported in pediatric populations (17-21) 
.   
 
The aim of our systematic review is therefore to investigate the predictors of glycaemic control in paediatric T1D populations in the first 
12 months following diagnosis.  The outcomes from our analyses may enable diabetes healthcare practitioners to consider a more 
focused and individualized approach to achieving HbA1c targets in the early months following the diagnosis of T1D in children and 
young people. 
 
METHODS 
 
This review is part of a series of systematic reviews of evidence on the determinants and influence of early glycemic control in 
childhood onset T1D (International Prospective Register for Systematic Reviews -PROSPERO Registration number: 
CRD42015024546). The study design for the linked  reviews is outlined in the published protocol (22). Review methods used are as 
described by the Evidence for Policy and Practice Information (EPPI) Centre for the rigorous conduct and reporting of systematic 
reviews for policy and practice (23).  
 
Search strategy, inclusion/exclusion and quality assessment criteria 
The search strategy for the linked reviews was designed in consultation with experts after initial iterative scoping searches, to 
maximize sensitivity and specificity in capturing relevant publications. Three sets of search terms were used relating to population 
(children and young people diagnosed with TID), exposure (terms to capture observational, intervention, qualitative studies and 
review articles relating to early diabetes control) and outcome (complications, mortality, change in glycemic levels or metabolic 
memory). Six electronic databases were double searched in parallel (VMP & HC), from inception to December 2014, without time 
period or language restrictions, by using a combination of free text and Thesaurus or MeSH (Medical Subject Headings) terms 
(supplementary table S1). This was supplemented by hand-searching reference lists and contacting authors of included and relevant 
studies which resulted in identifying nine (24-32) additional studies. 
 
For this review, we defined early glycemic control as HbA1c levels within the first 12 months (subdivided into 0-3 months and 4-12 
months) of T1D diagnosis as: 1) mean blood glucose concentrations fall dramatically in the first 3 months after diagnosis following the 
introduction of insulin therapy and thereafter tend to stabilize (33), 2) blood glucose concentrations during 0-3 months may partly 
reflect factors that relate to pre-diagnosis, such as access to healthcare, whereas the 4-12 month time period may include factors 
such as clinic expertise and insulin regimens, 3) diabetes clinics tend to gather and review clinical data of T1D patients at quarterly 
visits.  
  
Studies that described and quantified the association between early glycemic control AND predictors of early glycemic control in 
children and young people aged 0 to 19 years at baseline were included (supplementary table S2). We excluded studies of non-
humans, populations selected for other diseases; adults aged ≥19 years at baseline and other types of diabetes. We also excluded 
studies not reporting clinical outcomes or not describing an association with outcomes.  
 
The quality assessment criteria (supplementary table S3) were based on methods described by the EPPI Centre (23) where 
observational studies were scored based on six items focusing on both internal and external validity. Studies were classified as high, 
intermediate or low quality based on the number of quality criteria met (for observational studies: low: ≤2; intermediate: 3–4; high: 
≥5). 
 
Study selection 
To ensure high level of agreement and to minimize reviewer-related biases, a sample of titles, abstracts and articles were double 
screened (DC, RA and VMP). Full texts of abstracts appearing to meet the inclusion criteria were retrieved for further review and their 
inclusion/exclusion status was recorded. No foreign language papers were identified. Articles were re-examined (DC, RA and VMP) if 
there was uncertainty about inclusion criteria and disagreements were resolved at team meetings.  
 
Data extraction 
Studies meeting inclusion criteria were quality assessed, data extracted and analyzed by one reviewer (VMP). For quality assurance, 
all shortlisted studies were double reviewed, data extracted and analyzed by a second reviewer (DC and RA).  
 
For observational studies details of the predictor were extracted and the results were stratified by study design. From prospective or 
retrospective cohort studies, the association between the predictor and HbA1c at follow up points (from baseline) within 12 months of 
diagnosis was extracted. For cross sectional studies (XS), the association between the predictor and HbA1c at the reported time 
point was extracted (supplementary table S4). 
 
Data Synthesis 
Data was not meta-analyzed due to heterogeneity between studies and due to the potential influence of exposure on the wider 
determinants of health outcomes. However, we endeavored to synthesize the complex and diverse evidence graphically in a way 
similar to a forest plot. Evidence on the direction and strength of the association of predictors and correlates of early glycemic control 
was summarized using the harvest plot format, which allow a  summary of data that cannot be incorporated in a forest plot meta-
analysis (34).  The harvest plot combines data from several studies and displays the study size, quality and design in addition to 
demonstrating the effect and direction of the association.   
 
Each harvest plot bar (Figures 2a and 2b) represents a study. Some observational studies reported results of more than one 
predictor or correlate and were accordingly plotted. Predictors and correlates were grouped based on type (Demographic, biological, 
behavioral, psychosocial and healthcare). The numerical and alphabetical study id symbol above the bar represents the 
prospective/retrospective cohort studies and XS studies respectively. The color (black, dark grey and light grey) of bar represented 
quality of study, with lighter bars representing studies of low quality. The height of bar indicates the study size (small: n <100, medium: 
100 to 999, tall: ≥1000) and its position summarizes the direction and strength (statistical significance) of the association (+, 0, -). 
Statistically non-significant + and - associations were colour-coded in red and blue respectively and grouped under ‘0’.  Categorical 
 and continuous outcome variable results within studies were consistently recoded, such that a + symbolizes higher risk for poor 
glycemic control and a - symbolizes a lower risk for poor HbA1c levels (35, 36). The weight of the findings between studies was further 
summarized non-quantitatively as done previously (37, 38), to indicate the significance and greater confidence in the results; where 
three or more studies consistently reported the direction of the association of a potential predictor.  
 
RESULTS 
 
Search results 
The identified articles from individual databases (Medline via OVID, n = 13,039; Embase via OVID, n = 645; Web of Science via 
Thompson Reuters, n = 2,323; CINAHL via EBSCO, n = 984; Scopus via Elsevier, n = 1,540 and Cochrane library, n = 3,242) were 
imported into an Endnote file and de-duplicated, which resulted in 17,915 articles for further review. No interventional studies met the 
inclusion criteria. 20 observational studies were included in the review (Figure 1). 
 
Observational (Cohort and XS) studies characteristics and quality 
Evidence from observational (longitudinal cohort: n=15 and XS: n=5) studies, published between 1987 and 2015, have been 
summarized in supplementary tables S5 and S6 respectively. The observational studies were of high or intermediate quality. Six 
cohort studies provided high quality evidence (25, 26, 28-30, 32, 39, 40) and fourteen studies (longitudinal: n=9 (27, 31, 41-47) and 
XS: n=5 (2, 4, 24, 48-50) ) provided intermediate quality evidence. None of the studies were of low quality.   
 
There was vast heterogeneity between included studies in terms of study (population, design), outcome (measure, analyses) and 
follow-up. 10/15 of the longitudinal studies included in our review reported a single HbA1c outcome each during the 0-3 months or 4-
12 months follow-up period after diagnosis. 5/15 studies reported more than one  HbA1c measurement during the first 12 months of 
diagnosis as follows: One study reported HbA1c outcome monthly for 12 months (40), another reported monthly for first three months 
and quarterly thereafter (27). Two further studies reported at 6 and 12 months (45, 47), whereas Sochett et al reported follow-up at 
10 days, 1, 3, 6 and 12 months after diagnosis (31). However, for the purpose of this review, from these five studies, only the 
reported HbA1c outcome values, at or nearest to 3 or 12 months post diagnosis was included in our report. 
 
Geographical mapping and population characteristics of included studies 
Eight studies were conducted in USA (24-27, 30, 43-46, 49), one each in Canada (31) and New Zealand (39) and ten in Europe (four 
(4, 32, 48, 50) from Sweden, two (2, 41) from the UK, one each from Switzerland (47) and Italy (42), one involving seven European 
countries (28, 29) and one (40) involving 15 European countries and Japan). The total number of participants was approximately 
30,818 (longitudinal cohort: 15,975 and XS: 14,843, range 30 (41) to 8190 (50)). Five of the prospective cohort studies had less than 
100 participants (31, 41, 45-47). The age range of study population was 0 to 18 years (28, 32, 41, 48).Three studies excluded pre-
school aged children (4, 46, 47). Six observational studies (cohort: n=4 (40, 43, 46, 47) and XS: n=2 (2, 4)) were non representative 
of the general population as they included certain categories of children based on age, ethnicity, mother tongue and T1D duration. 
Included studies investigated various predictors and correlates of glycemic control in the first year of T1D diagnosis, using a variety of 
outcome measures.   
 
Predictors and correlates of glycemic control during the first year of diagnosis    
0-3 months after diagnosis of T1D (Figure 2a) 
 Older age (4, 30, 40, 43, 45, 48, 50) and female gender (30, 32, 41, 48, 50) were studied by more than five studies and were 
significantly associated with poor glycaemic control. At least two out of three studies reported associations with: non-white ethnicity 
(25, 30), autoantibody positivity (24, 40, 49), measures of deprivation or low socioeconomic status (SES) (25) and non-private health 
insurance (25, 44). Two studies reported an association with HbA1c diagnostic testing strategies pre 2004 (30) and a spring season 
of diagnosis (32).  
 
One out of three studies reported an association (24, 49) with C-peptide concentration at diagnosis while two reported no association 
(28, 31). Evidence on the asssociation with single parent family (25), child’s body mass index (BMI) (24, 41, 43, 49, 50), acidosis at 
diagnosis (43, 50), parental/child’s behaviour (47) and clinic factors (25, 43) were insufficient or inconsistent.  
 
4-12 months after diagnosis of T1D (Figure 2b) 
Older age (4, 40, 43), non-white ethnicity (25, 39, 40), single parent family (2, 25, 46), high HbA1c levels at diagnosis (40, 42, 43), 
increasing T1D duration (40, 42, 44, 47) and conventional insulin regimen (no insulin pump used) (25, 43, 44) were each studied by 
three or more studies and were strongly associated with poor glycaemic control 4-12 months after diagnosis.  
 
Gender (25, 40, 43, 45, 47), C-peptide concentrations (28, 31, 40) and ketoacidosis (25, 40, 43) at diagnosis were not associated 
with glycaemic control during this period. The role of health insurance (25, 43, 44), SES (2, 39, 47), BMI (2, 25, 40, 41, 43, 44), 
autoantibody positivity (25), comorbidities (coeliac, thyroid or other disease) (2), child’s/parental behaviour (47), parental ill health  (2, 
39) and clinic factors (2, 25) are unclear due to inconsistentcy of reporting associations or poor evidence.  
 
DISCUSSION 
 
We systematically investigated predictors of glycemic control at 0-12 months following the diagnosis of childhood onset T1D. The 
identified evidence came from observational studies published between 1987 and 2015 and from more economically developed 
countries. There have been no interventional studies of these predictors of glycemic control, emphasizing the utility of synthesizing 
appropriate evidence from a variety of relevant study designs. Also, there was an inconsistency of time points of the reported 
associations across studies. Furthermore, the associations between predictor and outcomes reported by observational studies should 
be interpreted with caution as they do not imply causal relationships. However, harvest plot analyses allowed us to meaningfully 
combine such studies and demonstrate the strength (number of studies supporting the association) and direction (positive or 
negative) of the associations. 
Our review found that older age at diagnosis (>10 years) was associated with poorer glycemic control throughout the first year of 
diagnosis. This may relate to a complex interaction of factors such as increased insulin resistance (51) and psychosocial changes 
such as decreased adherence to management plans that occur during adolescence (52).  
 
Female gender was consistently reported by more than five longitudinal studies (4, 30, 32, 41, 48, 50) to be associated with poor 
early glycaemic control, within first three months of diagnosis, as opposed to no association reported by five out of eight studies after 
this time period (25, 40, 43, 45, 47). If genuine, this association may partly relate to reduced insulin sensitivity during puberty (53), 
increased insulin omission, eating disorders and greater psychological disturbances (51, 54, 55) in females compared to males.     
 
The associations between ethnicity (25, 30, 39, 40), low SES (2, 25, 39) and children not living with biological parents (2, 25, 46) and 
poor early glycemic control is consistent with other studies that did not meet our review inclusion criteria (56-62). The association 
 between ethnicity and glycemic control may be related to differences in cultural and lifestyle patterns (63), sub-optimal treatments 
and resistance to changing to new therapies (56) and reduced use of insulin pump therapy (64). Other studies have also shown 
biological differences between ethnic groups relating to hemoglobin glycation (65, 66).  
 
Higher HbA1c levels at diagnosis were consistently associated with poorer early glycemic control 4-12 months after T1D diagnosis. 
DKA and higher HbA1c may indicate a delay in the diagnosis of T1D and a later presentation to medical services (67, 68). There 
have been attempts to increase public and primary care awareness of the symptoms of T1D and the ease of diagnostic tests (69). 
However government directed initiatives may be required to ensure genuine change in practice and behaviors.  
 
We found that most studies reported no association between C-peptide concentrations and early glycaemic control and this may 
reflect methodological differences in its measurement. Low C-peptide concentrations as a measure of low endogenous insulin 
secretion (70) may represent a more aggressive autoimmune destruction of pancreatic beta cells (71) and are associated with higher 
mean HbA1c levels and future vascular complications (72, 73). These disparities require further investigation.  
 
Our review indicates that the type and dosage of insulin regimen were strong predictors of glycemic control. Absence of pump 
therapy (43, 44), an insulin dose ≥0.8/kg/day (25) and lower frequency of daily self-monitored blood glucose tests per day (25) were 
associated with poorer early glycemic control. A complicating factor in interpreting these observations is that earlier use of intensive 
diabetes therapy may also reflect a category of patients who have a shorter honeymoon period and/or more severe phenotype. It 
would be important to investigate whether any benefit of early intensive diabetes management through improved HbA1c levels tracks 
in later years and results in reduced vascular complications risk.  
 
Children with parental health problems and with family history of T1D, had poorer glycemic control (2, 39) which may be due to 
inherent genetic predisposition to adverse health outcomes (74), but also more likely to be due to behavioral predisposition or 
behavioral factors such as parental worry about hypoglycemia.  
 
Evidence on the association between clinic factors and early glycemic control was inconclusive (2, 25, 43). Studies have indicated 
that diabetes teams play a significant role in achieving glycemic targets (75, 76). It is unclear if people with T1D living closer to their 
diabetes clinic are more likely to attend clinic than those living further away. Non-attendance is associated with poorer adherence to 
treatment regimens and an elevated risk for diabetes complications (77, 78) particularly in ethnic minorities and those from lower SES 
in countries with healthcare systems based on the out-of-pocket model. These patients tend to have higher HbA1c and other markers 
of future vascular diseases and therefore clinic factors needs further investigation.        
 
Two out of three USA based longitudinal studies found that non-private health insurance was significantly associated with poor 
glycaemic control in the first year of diagnosis (25, 44). Parental and child’s behavior in relation to early glycemic control needs 
further investigation as these were subjectively investigated by one prospective study (47).  Month and season of diagnosis in 
children was associated with early glycemic control and mean HbA1c at diagnosis was observed to be highest in May and lowest in 
October (32). The mechanisms that explain these associations are unclear and require further investigation. 
  
Strengths and limitations of the review 
To our knowledge, this is the first review to robustly investigate published literature on the predictors and correlates of early glycemic 
control in childhood onset T1D. Furthermore, strict published pre-set systematic review procedures have been adhered to throughout 
 the process. No period restrictions were applied to literature search strategy and included studies were published between 1987 and 
2015 suggesting the encompassment of thorough and up-to-date research in this area. We have taken utmost care to minimize study 
selection, reviewer related bias. However, publication bias cannot be ruled out. We were unable to meta-analyze the systematically 
gathered evidence or measure the effect of each predictor in reducing or increasing the HbA1c levels during the first year of 
diagnosis. However, our review included observational studies and encountered heterogeneity across the studies (varied 
demographics of the study population, study setting, quality, designs, analyses, outcome and follow-up measures), allowing us to 
display the details of these differences graphically through harvest plots. The overall quality of the included observational studies was 
intermediate or high and most of the results from the studies are generalizable, but all of the associations between predictors and 
outcome cannot be interpreted as showing causal relationships, due to the limitations of the study designs.  
 
CONCLUSIONS AND IMPLICATIONS FOR POLICY/PRACTICE/FURTHER RESEARCH 
 
Quantitative evidence identified characteristics of children with T1D who are at high risk of poor early glycemic control.  
Characteristics such as age, gender, BMI, ethnicity and SES are not modifiable, however they do help in identifying those children 
and young people with T1D at high risk, for whom individualized care plans can be put in place to ensure early target HbA1c levels 
are attained. Biomarkers potentially indicating a delay in diagnosis of T1D (higher HbA1c and DKA at presentation) appear to be 
associated with poorer subsequent glucose control. Suboptimal glycemic control has been shown to track and therefore puts children 
at higher risk of developing complications. Intensive insulin therapy has shown beneficial effect in glycemic control during the first 
year of diagnosis, so implementation of updated clinical practice guidance would be advantageous. 
 
Review updating plans 
The review will be updated if significant new evidence becomes available and results of the update review will be disseminated 
through peer-reviewed publications, conference presentations and at meetings.  
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 Figure 1: Flowchart presenting an overview of the search results. 
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 Fig. 2a: Predictors of glycaemic control 0-3 months following diagnosis of type 1 diabetes in children and young people.  
(A + denotes HIGHER risk of poor glycaemic control) 
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Figure 2b: Predictors of glycaemic control 4-12 months following diagnosis of type 1 diabetes in children and young people.   
       (A + denotes HIGHER risk of poor glycaemic control) 
 
Predictors 
  
Significant negative 
association 
(-) 
Non-significant /  No 
association   
 (0) 
Significant positive 
association  
(+) 
     
DEMOGRAPHIC PREDICTORS    
Age at diagnosis: older versus younger 
   
      6       █ █ █ 
 █   
     █  █ █ █  
     █  
  B  1 4a  7 11 13   m 
         █ █ █       █ █ █ 
  █ █ █ █ █ █ █ █ 
  █ █ █ █ █ █  
          C  8 9   m   
        █ █ █ █       █ █ █ 
        █ █ █ █ █ █ 
        █ █ █ █ 
Gender: female versus male 
    
     4a 9  8 11 13m  m  
        █ █ █       █ █ █ 
      █ █ █ █ █ █ █ 
      █ █ █ █ ██ 
           6  B  55  m  
        █ █ █        █ █ 
        █ █   █  █ █ █ 
        █ █ █ █ 
Ethnicity: non-white versus white 
     
          4a 6   9 m  
         █ █ █       █ █ █ 
        █ █ █  █  █ █ █ 
        █ █ █ █ 
Health insurance: non-private versus private 
    
      8     m   
         █ █ █       █ █ █ 
        █ █ █ █ █ 
        █  █ 
          4a 10    m  
        █ █ █       █ █ █ 
        █ █   █ █ █ 
        █ █  
Most deprived B, low SES6,13 
    
         B 13m  m  
        █ █ █       █ █ █ 
        █ █ █ █ █ 
        █ █ █ 
          6     
█ █ █ 
        █   █  █ █ █ 
        █ █ 
Area of residence: rural versus urban  
   
       B █ █ █ 
 █   
      █ █ █ █  
      █    
Family type: One parent versus two 
     
          4a B  12m m 
         █ █       █ █ █ 
        █ █   █  █ █ █ 
        █ █ ██ 
 
BIOLOGICAL PREDICTORS 
Puberty 
    
      4a     m   
         █ █ █       █ █ █ 
         █  █ █ █ █ 
         █  
          
 
BMI: high versus low  
   
         8   m  
        █ █ █       █ █ █ 
        █  █  █ █ █ 
        █  
       4a 9 10   m   
        █ █ █       █ █ █ 
        █ █ █ █ █ █ █ 
        █ █ █ █ 
          B  5  m  
        █ █ █       █ █ █ 
        █  █  █ █ █ 
        █ █ █ 
HbA1c at diagnosis: high versus low 
    
       4a 7   m   
        █ █ █       █ █ █ 
         █ █  █ █ █ 
         █ █ █ 
           8   9 m   
        █ █ █       █ █ █ 
        █ █   █  █ █ █ 
        █ █ █ 
Increasing T1D duration from 0 to 12 months post diagnosis 
    
       1 4b 814 15   m  
        █ █ █       █ █  
        █ █ █ █ █ █ █ █ 
        █ █ █ █ █  █ 
           7  9 10 13 m   
         █ █ █       █ █ █ 
         █ █ █  █ █ █ 
         █ █ █ █  
Autoantibody positivity (anti-islet, GADA, IA, ICA) 
    
        4a     m   
        █ █ █       █ █ █ 
        █ █ █ █ █ 
        █ █  
C-peptide at baseline: low versus high 
    
      1 9  15m  m  
         █ █ █       █ █ █ 
        █ █  █ █ █ █ 
        █ █ █  █           █ 
Low bicarbonate9 , acidosis8 or Diabetic Ketoacidosis4a,B at diagnosis 
    
       4a 9  B 8 m   
        █ █ █       █ █ █ 
        █ █ █ █ █ █ █ █ 
        █ █ █ ██ █ 
Co-morbidities at diagnosis (Coeliac diseaseB1, Thyroid disease B, Other physical co-morbiditiesB2 
    
      B1 B2   m 
         █ █ █       █ █ █ 
        █ █  █ █ █ █ 
        █ █ █ 
           B 
         █ █ █       █ █ █ 
        █ █ █ █ 
        █  █ 
 
BEHAVIORAL PREDICTORS 
Behaviour (of parents13, child13a) influencing poor glycaemic control  
    
      13 13am1  m  
█ █       █ █ █ 
        █ █ █ █ 
        █ ██  
 
PSYCHOSOCIAL PREDICTORS 
Family history of T1D6,B, enduring parental health problemsB2 
    
      B B2       m  
        █ █       █ █ █ 
        █ █ █ █ █ █ 
        █ █  █ 
           6    m   
         █ █ █       █ █ █ 
        █ █  █ █ █ 
        █  █ 
Child’s welfare concerns 
     
           B    m   
         █ █ █       █ █ █ 
        █ █  █ █ █ 
        █ █ 
 
HEALTHCARE PREDICTORS 
Insulin regimen (no pump use10, 8), Insulin dose ≥0.8/kg/day4a, 15, higher frequency of daily self-monitored blood glucose tests >4/day4a1 
   
     4a1     
 █   
     █ █ █ █  
     █  
      15  m  
        █ █ █       █ █ █ 
        █ █ █ █ 
        █ █ 
           4a 8 10    m   
         █ █ █       █ █ █ 
         █ █ █  █  █ █ █ 
         █ █ █ █ 
Clinic factors: Distance from clinic B, Clinic site with fewer therapeutic services4a , fewer visits to diabetes clinic (range 1-6/year)4a1  
    
       B 4a1       m   
        █ █ █       █ █ █ 
        █ ██ █ █ █ 
        █ █ 
           4a    m  
         █ █ █       █ █ █ 
         █   █  █ █ █ 
         █ █ 
 
T1D: Type 1 diabetes; BMI: Body mass index; SES: Socio-economic status; GADA: Glutamic acid decarboxylase antibodies; ICA: Islet cell antibodies; IA: insulin antibodies   
 
Prospective/ retrospective cohort studies: 1: Barker 2014 (28) & Lauria 2015 (29); 2: Clements 2014 (30); 3: Hanberger 2014 (32); 4a, 4a1: Redondo 2014 (25); 4b: Cengiz 2014 (26); 5: Davis 2012 
(41); 6: Cutf ield 2011 (39); 7: Giordano 2011 (42); 8: Viswanathan 2011 (43); 9: Mortensen 2010 (40); 10: Beck 2009 (40); 11: Hochhauser 2008; 12 (45): Frey 2007 (46); 13: Vollrath 2007; 14 (47): Chase 
2004 (27); 15: Sochett 1987 (31) 
 
Cross sectional studies: A: Akesson 2014 (50); B, B1, B2: Law es 2014 (2); C: Samuelsson 2014 (4); D: Sammuelsson 2013 (48); E: Redondo 2013 (24) & 2012 (49) 
 
Note: 
1. Position of bar based on direction and strength of association (statistically signif icant positive or negative association (+ / -), statistically non- signif icant (NS) positive or negative association or no 
association (0), study ID’s in red and blue fonts representing NS + and NS - respectively). 
2. Results for categorical and continuous outcome variables coded so a + denotes HIGHER risk of poor glycaemic control (i.e. higher HbA1c levels is view ed as positive association of predictor/correlate) 
and a - denoted a LOWER risk for poorer glycaemic control. 
3. Height of bar represents size of study (small: n <100, medium: 100 to 999, tall: ≥1000)  
4. Colour represents quality of study: Black, dark grey and light grey (based on total quality assessment score) - High: met f ive to six quality criteria, Intermediate: met three or four quality criteria, Low : met 
tw o or less quality criteria  
5. Study id symbol on top of bar (numerical for prospective/retrospective cohort studies and alphabetical for XS studies).  
 Supplementary table S1: Electronic database search strategy 
 
I.  Scopus (via Elsevier) (17/12/2014) 
1. ( TITLE-ABS-KEY ( ( {early intensive}  OR  tight  OR  glycemic  OR  glycaemic  OR  glucose  OR  diabetes  OR  strict )  W/2  control )  OR  TITLE-ABS-
KEY ( insulin  W/2  ( use*  OR  injection*  OR  dose*  OR  pump* ) )  OR  TITLE-ABS-KEY ( glycosylat*  OR  {HbA1c}  OR  a1c  OR  hemoglobin  a  OR  
haemoglobin  OR  {HbA(1c)} )  OR  TITLE-ABS-KEY ( ( intensive  OR  conventional  OR  standard  OR  regular  OR  optimised  OR  usual  OR  routine 
)  W/2  ( care  OR  treatment  OR  therapy  OR  intervention  OR  management ) )  OR  TITLE-ABS-KEY ( hyperglycaemia  OR  hypoglycaemia ) )  
AND  ( TITLE-ABS-KEY  OR ( {Diabetes complication*}  OR  {side effects}  OR  {adverse events}  OR  glycemia  OR  glycaemia  OR  {hyper glycemia}  
OR  {hyper glycaemia}  OR  hyperglycemia  OR  hyperglycaemia  OR  {hypo glycemia}  OR  {hypo glycaemia}  OR  hypoglycemia  OR  hypoglycaemia 
)  OR  TITLE-ABS-KEY ( ketosis  OR  {diabetic ketoacidosis}  OR  dka  OR  {nonketotic hyperosmolar coma}  OR  {insulin resistance}  OR  
{autoimmune disease*}  OR  {auto immune disease} )  OR  TITLE-ABS-KEY ( {urine albumin}  OR  microalbuminaria  OR  macroalbuminuria  OR  
{renal disease*}  OR  {kidney disease*}  OR  {diabetic nephropathy}  OR  nephropathy  OR  dialysis )  OR  TITLE-ABS-KEY ( {foot ulcer}  OR  
amputation )  OR  TITLE-ABS-KEY ( retinopathy  OR  blindness  OR  {cardiovascular disease*}  OR  mi  OR  {myocardial infarction*}  OR  stroke*  OR  
{coronary artery disease*} )  OR  TITLE-ABS-KEY ( {cerebrovascular disease*}  OR  {peripheral vascular disease*}  OR  {blood pressure}  OR  bp  OR  
statin*  OR  death  OR  mortality ) )  AND  ( TITLE-ABS-KEY ( pediatric  OR  paediatric  OR  child*  OR  {young people}  OR  youth  OR  {young adult*}  
OR  juvenile  OR  {insulin dependent}  OR  labile  OR  brittle  OR  {sudden onset}  OR  autoimmune  OR  {auto immune}  OR  {non insulin dependent}  
OR  uncontrolled  OR  {newly diagnosed}  OR  {new diagnosis}  OR  {inception diabetes} ) )  AND  ( TITLE-ABS-KEY ( dm1  OR  {diabetes mellitus 1}  
OR  {diabetes mellitus}  W/2  {type 1} )  OR  t1d  OR  t1dm  OR  iddmor  {type 1} )  AND  TITLE-ABS-KEY ( metabolism  OR  {metabolic memory} )  
2 TITLE-ABS-KEY ( metabolism  OR  {metabolic memory} ) 
3 (TITLE-ABS-KEY or ({Diabetes complication*} or {side effects} or {adverse events} or glycemia or glycaemia or {hyper glycemia} or {hyper glycaemia} 
or hyperglycemia or hyperglycaemia or {hypo glycemia} or {hypo glycaemia} or hypoglycemia or hypoglycaemia) or TITLE-ABS-KEY (ketosis or 
{diabetic ketoacidosis} or DKA or {nonketotic hyperosmolar coma} or {insulin resistance} or {autoimmune disease*} or {auto immune disease}) or 
TITLE-ABS-KEY ({urine albumin} or microalbuminaria or macroalbuminuria or {renal disease*} or {kidney disease*} or {diabetic nephropathy} or 
nephropathy or dialysis) or TITLE-ABS-KEY ({foot ulcer} or amputation) or TITLE-ABS-KEY (retinopathy or blindness or {cardiovascular disease*} or MI 
or {myocardial infarction*} or stroke* or {coronary artery disease*}) or TITLE-ABS-KEY ({cerebrovascular disease*} or {peripheral vascular disease*} or 
{blood pressure} or BP or statin* or death or mortality)) 
4 (TITLE-ABS-KEY (({early intensive} or tight or glycemic or glycaemic or glucose or diabetes or strict) W/2 control) OR TITLE-ABS-KEY (insulin W/2 
(use* or injection* or dose* or pump*)) OR TITLE-ABS-KEY (glycosylat* or {HbA1c} or A1c or Hemoglobin A or haemoglobin or {HbA(1c)}) OR TITLE-
ABS-KEY((intensive or conventional or standard or regular or optimised or usual or routine) W/2 (care or treatment or therapy or intervention or 
management)) OR TITLE-ABS-KEY (hyperglycaemia or hypoglycaemia)) 
5 ( TITLE-ABS-KEY ( pediatric  OR  paediatric  OR  child*  OR  {young people}  OR  youth  OR  {young adult*}  OR  juvenile  OR  {insulin dependent}  
OR  labile  OR  brittle  OR  {sudden onset}  OR  autoimmune  OR  {auto immune}  OR  {non insulin dependent}  OR  uncontrolled  OR  {newly 
diagnosed}  OR  {new diagnosis}  OR  {inception diabetes} ) )   
6 ( TITLE-ABS-KEY ( dm1  OR  {diabetes mellitus 1}  OR  {diabetes mellitus}  W/2  {type 1} )  OR  t1d  OR  t1dm  OR  iddmor  {type 1} )  
 
 
 
II.  Cochrane Library (17/12/2014) 
#1
  
MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees 
#2
  
DM1 or diabetes mellitus 1 or diabetes mellitus type 1 or T1D or T1DM or IDDM 
#3 type 1 or paediatric or child or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or autoimmune 
or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception diabetes  
#4
  
#1 or #2 or #3 
#5
  
MeSH descriptor: [Blood Glucose] explode all trees  
#6 MeSH descriptor: [Hemoglobin A, Glycosylated] explode all trees  
#7
  
MeSH descriptor: [Hypoglycemia] explode all trees  
#8
  
MeSH descriptor: [Hyperglycemia] explode all trees 
#9 #5 or #6 or #7 or #8   
#10
  
early intensive or tight or glycemic or glucose or diabetes or strict control  
#11 insulin use or injection or dose or pump  
   
#12 glycosylate or HbA1c or A1c or Hemoglobin A or HbA1c  
#13 intensive or conventional or standard or regular or optimised or usual or routine care or treatment or therapy or intervention or management   
#14
  
#9 or #10 or #11 or #12 or #13  
#15
  
MeSH descriptor: [Diabetes Complications] explode all trees 
#16
  
adverse effects or complications   
#17
  
MeSH descriptor: [Ketosis] explode all trees  
#18
  
MeSH descriptor: [Insulin Resistance] explode all trees 
#19 MeSH descriptor: [Autoimmune Diseases] explode all trees 
#20
  
MeSH descriptor: [Albuminuria] explode all trees  
#21
  
MeSH descriptor: [Kidney Diseases] explode all trees 
#22
  
MeSH descriptor: [Dialysis] explode all trees  
#23
  
MeSH descriptor: [Blindness] explode all trees 
#24
  
MeSH descriptor: [Cardiovascular Diseases] explode all trees 
#25
  
MeSH descriptor: [Cerebrovascular Disorders] explode all trees 
#26 MeSH descriptor: [Blood Pressure] explode all trees 
#27
  
MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees 
#28
  
MeSH descriptor: [Mortality] explode all trees 
#29
  
Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or DKA 
or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin 
excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot  ulcer or amputation or 
retinopathy or blindness or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or 
peripheral vascular disease or blood pressure or BP or statin or death or mortality   
#30
  
#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29  
#31
  
metabolism   
#32
  
metabolic memory  
#33
  
#31 or #32   
#34
  
#4 and #9 and #14 and #30 and #33   
 
 
 
III.  CINAHL (via EBSCO) (16/12/2014) 
S34  S4 AND S14 AND S30 AND S33   
S33  S31 OR S32   
S32  "metabolic memory"   
S31  MJ metabolism   
S30  S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29   
 S29  
diabetes complication or diabetes complication* or side effects or adverse events or glyc#emia or hyper glyc#emia or hyperglyc#emia or hypo 
glyc#emia or hypoglyc#emia or ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* 
or urine albumin or microalbuminaria or macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or 
foot ulcer or amputation or retinopathy or blindness or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or 
cerebrovascular disease* or peripheral vascular disease* or blood pressure or BP or statin* or death or mortality  
S28  (MH "mortality+")   
S27  (MH "statins+")   
S26  (MH "blood pressure+")   
S25  (MH "cerebrovascular disorders+")   
S24  (MH "stroke+")   
S23  (MH "cardiovascular diseases+")   
S22  (MH "blindness+")   
S21  (MH "dialysis+")   
S20  (MH "kidney diseases+")   
S19  (MH "Albuminuria")   
S18  (MH autoimmune diseases+)   
S17  (MH insulin resistance+)   
S16  
(MH "diabetic angiopathies+") OR (MH "diabetic cardiomyopathies") OR (MH "diabetic coma+") OR (MH "diabetic ketoacidosis") OR (MH "diabetic 
neuropathies+")   
S15  (MH "diabetes mellitus/co")   
S14  S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13   
S13  
(intensive OR conventional OR standard OR regular OR optimi#ed OR usual OR routine) N2 (care OR treatment OR therapy OR intervent ion OR 
management)   
S12  glycosylat* OR HbA1c OR A1c OR H#emoglobin A OR HbA#1c   
S11  insulin N2 (use* OR injection* OR dose* OR pump*)   
S10  (“early intensive” OR tight OR glyc#emic OR glucose OR diabetes or strict) N2 control)   
S9  (MH "Hyperglycemia+")   
S8  (MH "Hypoglycemia+")   
S7  MH blood glucose   
S6  MH hemoglobin a, glycosylated   
S5  (MH "Glycemic Control")   
S4  S1 OR S2 OR S3   
S3  
("type 1" OR p#ediatric OR child* OR "young people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden 
onset" OR autoimmune OR "auto immune" OR "non insulin dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) N5 
diabetes   
S2  DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" N2 type 1) OR T1D or T1DM or IDDM   
S1  (MH "Diabetes Mellitus, Type 1+")   
 
 
 
IV.  Web of Science (via Thomson Reuters) (16/12/2014) 
1 
TOPIC: ((DM1 OR "diabetes mellitus 1" OR ("diabetes mellitus" NEAR/2 "type 1") OR T1D or T1DM or IDDM) OR TOPIC: (("type 1" OR p$ediatric OR 
child* OR "young people" OR youth OR "young adult" OR juvenile OR "insulin dependent" OR labile OR brittle OR "sudden onset" OR autoimmune OR 
"auto immune" OR "non insulin dependent" OR uncontrolled OR "newly diagnosed" OR "new diagnosis" OR inception) NEAR/5 diabetes)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
2 
TOPIC: (TOPIC: ((“early intensive” OR tight OR glyc$emic OR glucose OR diabetes or strict) NEAR/2 control) OR TOPIC: (insulin  NEAR/2 (use* OR 
injection* OR dose* OR pump*)) OR TOPIC: (glycosylat* OR HbA1c OR A1c OR H$emoglobin A OR HbA$1c) OR TOPIC: ((intensive OR conventional 
OR standard OR regular OR optimi$ed OR usual OR routine) NEAR/2 (care OR treatment OR therapy OR intervention OR management)) OR TOPIC: 
(hyperglyc$emia OR hypoglyc$emia)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
3 
TOPIC: (TOPIC: (“Diabetes complication*” OR “side effects” OR “adverse events” OR glyc$emia OR “hyper glyc$emia” OR hyperglyc $emia OR “hypo 
glyc$emia” OR hypoglyc$emia OR ketosis OR “diabetic ketoacidosis” OR DKA OR “nonketotic hyperosmolar coma” OR “insulin resistance” OR 
“autoimmune disease*” OR “auto immune disease” OR “urine albumin” OR microalbuminaria OR macroalbuminuria OR “renal disease*” OR “kidney 
disease*” OR nephropathy OR dialysis OR “foot ulcer” OR amputation OR retinopathy OR blindness OR “cardiovascular disease*” OR MI OR 
“myocardial infarction*” OR stroke* OR “coronary artery disease*” OR “cerebrovascular disease*” OR “peripheral vascular disease*” OR “blood 
pressure” OR BP OR statin* OR death OR mortality)) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
4 TOPIC: (TOPIC: (metabolism OR "metabolic memory" OR metabolic)) 
 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, CCR-EXPANDED, IC Timespan=All years 
 
 
 
V.  EMBASE (via OVID) (16/12/2014) 
1 exp insulin dependent diabetes mellitus/ 
2 
(DM1 or diabetes mellitus 1 or (diabetes mellitus adj2 type 1) or T1D or T1DM or IDDM).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]  
3 
((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or britt le or sudden onset or 
autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
4 1 or 2 or 3 
5 exp glycosylated hemoglobin/ 
6 exp glucose blood level/ 
7 exp hypoglycemia/ 
8 exp hyperglycemia/ 
9 
((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword]  
10 
(insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
11 
(glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] 
12 
((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or 
management)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device 
trade name, keyword] 
13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14 
diabetic angiopathy/ or diabetic cardiomyopathy/ or diabetic coma/ or diabetic foot/ or diabetic hypertension/ or diabetic ketoacidosis/ or diabetic 
macular edema/ or diabetic nephropathy/ or diabetic neuropathy/ or diabetic obesity/ or diabetic retinopathy/ or impaired glucose tolerance/ or 
"maternally inherited diabetes and deafness"/ or nonketotic diabetic coma/ or wolfram syndrome/ 
15 exp diabetes mellitus/co [Complication] 
16 exp diabetes mellitus/si [Side Effect] 
17 exp insulin resistance/ 
18 exp autoimmune disease/ 
19 exp albuminuria/ 
20 exp kidney disease/ 
21 exp dialysis/ 
22 exp blindness/ 
23 exp cardiovascular disease/ 
24 exp cerebrovascular disease/ 
25 exp blood pressure/ 
26 exp hydroxymethylglutaryl coenzyme A reductase inhibitor/ 
27 exp mortality/ 
28 
(Diabetes complication* or side effects or adverse events or glyc?emia or hyper glyc?emia or hyperglyc?emia or hypo glyc?emia or hypoglyc?emia or 
ketosis or diabetic ketoacidosis or DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease* or urine albumin or 
microalbuminaria or macroalbuminuria or renal disease* or kidney disease* or diabetic nephropathy or nephropathy or dialysis or foot ulcer or 
amputation or retinopathy or blindness or cardiovascular disease* or MI or myocardial infarction* or stroke* or coronary artery disease* or 
cerebrovascular disease* or peripheral vascular disease* or blood pressure or BP or statin* or death or mortality).mp. [mp=ti tle, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
29 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
30 memory/ 
31 
metabolic memory.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
32 30 or 31 
33 4 and 13 and 29 and 32 
 
 
 
VI.  Medline (via OVID) (16/12/2014) 
 1 exp Diabetes Mellitus, Type 1/ 
2 
(((DM1 or diabetes mellitus 1 or diabetes mellitus) adj2 type 1) or T1D or T1DM or IDDM).mp.  [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
3 
((type 1 or p?ediatric or child* or young people or youth or young adults or juvenile or insulin dependent or labile or brittle or sudden onset or 
autoimmune or auto immune or non insulin dependent or uncontrolled or newly diagnosed or new diagnosis or inception) adj5 diabetes).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
4 1 or 2 or 3 
5 exp Blood Glucose/ or exp Hemoglobin A, Glycosylated/ or exp Hypoglycemia/ 
6 exp Hyperglycemia/ 
7 
((early intensive or tight or glyc?emic or glucose or diabetes or strict) adj2 control).mp. [mp=title, abstract, original tit le, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]  
8 
(insulin adj2 (use* or injection* or dose* or pump*)).mp. [mp=title, abstract, original title, name of substance word, subjec t heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]  
9 
(glycosylat* or HbA1c or A1c or H?emoglobin A or HbA?1c).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]  
10 
((intensive or conventional or standard or regular or optimi?ed or usual or routine) adj2 (care or treatment or therapy or intervention or 
management)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
11 5 or 6 or 7 or 8 or 9 or 10 
12 exp Diabetes Complications/ 
13 adverse effects.fs. 
14 complications.fs. 
15 exp Ketosis/ 
16 exp Insulin Resistance/ 
17 exp Autoimmune Diseases/ 
18 exp Albuminuria/ 
19 exp Kidney Diseases/ 
20 exp Dialysis/ 
21 exp Blindness/ 
22 exp Cardiovascular Diseases/ 
23 exp Cerebrovascular Disorders/ 
24 exp Blood Pressure/ 
25 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ 
26 exp Mortality/ 
27 
(Diabetes complications or side effects or adverse events or glycaemia or hyper glycaemia or hypo glycaemia or ketosis or diabetic ketoacidosis or 
DKA or nonketotic hyperosmolar coma or insulin resistance or autoimmune disease or urine albumin or urine albumin creatinine ratio or urine albumin 
excretion or microalbuminuria or macroalbuminuria or renal disease or diabetic nephropathy or nephropathy or dialysis or foot ulcer or amputation or 
retinopathy or blindness or cardiovascular disease or MI or myocardial infarction or stroke or coronary artery disease or cerebrovascular disease or 
peripheral vascular disease or blood pressure or BP or statin or death or mortality).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 
28 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
29 4 and 11 and 28 
30 metabolism.fs. 
31 
metabolic memory.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,  protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
32 30 or 31 
33 29 and 32 
 
  
 Table S2: Inclusion and exclusion criteria for review of evidence on what factors predict early HbA1c? 
 
Inclusion Criteria Exclusion Criteria 
- Interventional studies (RCT’s and non-RCT’s) targeting 
glycaemic control (within 2 years of diagnosis of T1D) and 
described an association with health outcomes  
- Non-intervention/observational i .e. cohort and cross 
sectional (XS) studies that quantified the association 
between early glycaemic control (within 2 years of 
diagnosis of T1D) AND risk of future complications in 
children and young people aged 0 to 25 years at baseline  
- Qualitative studies that give a deeper background 
understanding on the topic 
 
- Non-human studies 
- Selection of population based on other diseases/co-
morbidities  
- Adults aged more than 25 years at baseline. 
- Studies on T2D  
- Quantitative studies not reporting clinical outcomes  
- Quantitative studies that measured glycaemic 
control but did not describe an association with 
outcome variables 
 
 
Table S3: Quality assessment criteria  
For observational (prospective/retrospective cohort and cross sectional) 
studies 
Total quality assessment score (maximum of 6) was derived for fulfilment of following criteria: 
 
1) More than 50 participants analysed; 
2) Studies representing general population 
3) Prospective study design 
4) Adjusted/multivariate analysis 
5) Objective measure of outcome 
6) Objective measure of exposure. 
 
Table S4: Details of data extracted from included studies 
 
Observational studies (cross-sectional and prospective/retrospective cohort) 
- Study id  
- Author  
- Year  
- Country  
- Age Range  
- Average age  
- Sex (Male: Female ratio)  
- Ethnicity  
- Socioeconomic status  
- Design (Cross sectional/Prospective)  
- Number of participants  
- Sample/recruitment e.g general population representative sample or specialist groups,  
- Exposure  examined  
- Measurement of Exposure  
- Measurement conducted by Level of glycemic control  
- Setting (home, primary care, secondary care)   
- Outcome (complications, metabolic memory - separate row for each outcome investigated),  
- Measurement of outcome (objective)   
- Analysis  
- Effect 
- Author email  
- Comments  
 
 
 
  
 Table S5:  Predictors of early glycaemic control in childhood onset T1D: Evidence from longitudinal studies  
 
REP: Representative; NON REP: Non representative; T1D: type 1 diabetes; BMI: Body Mass Index; SES: Socio-economic status; f/u: Follow up; SD: Standard deviation; ++: statistically significant positive association; + or - : 
statistically non- significant positive or negative association; /: no association. 
No Author, year 
and country 
Study design/ 
name  
Population and 
setting 
Age range 
of study 
population 
at 
diagnosis 
Follow-up 
period 
Predictor Outcome Measure/ 
analyses 
Association  Quality 
assessment 
score (max 6) 
and 
comments 
1 Barker 2014 
(28) 
& Lauria 
2015 (29) 
 
Seven  
countries in 
Europe 
(Belgium, 
Leuven, 
Hungary, 
Spain, 
Sweden, 
Germany, 
Italy). 
Prospective 
cohort 
REP: 842 and 2264 
children 
respectively (58% 
and 55% males 
resp.) with T1D 
from 
registries/database
s in seven European 
countries (Belgium, 
Leuven, Hungary, 
Spain, Sweden, 
Germany, Italy). 
 
  
0- 18 years 1 and 5 
years 
Biological:  Age at diagnosis 0 - 18 at 
diagnosis, 1and 5 years f/u 
 
 
Biological:  fasting C Peptide at diagnosis, 
1and 5 years f/u 
 
 
 
 
Biological:  T1D duration  0,1, 5 years 
Association with 
HbA1c levels 
Mean (SD) 
 
 
 
Receiver 
operating 
characterist
ics (ROC) 
analysis. 
 
Mean (SD) 
 
+ HbA1c levels increased 
with age. Statistical 
significance not reported 
 
/ 
 
 
 
 
 
+ at diagnosis 
- at 1 year  
+ at 5 years. Statistical 
significance not reported 
High (5). 
Did not 
include 
adjusted/mult
ivariate 
analysis  
 
2 Clements 
2014 (30) 
 
USA 
Prospective 
cohort 
REP: 2218 children 
and young people 
(52.6% male), 
Ethnicity: 86.1% 
non-Hispanic 
Caucasian, 8.9% 
non-Hispanic 
African-American, 
5% other or 
Hispanic), 
registered between 
1993 and 2009 at 
the Children’s 
Mercy Hospital 
Type 1 diabetes in 
paediatrics 
database, USA 
0-20 years 
 
Mean age 
at 
diagnosis: 
9.0 ±4.1 
years 
1.5 and 5 
years 
Biological:  Age at diagnosis 0-20 years  
 
 
 
Biological: Gender: female 
 
 
Biological: Duration of T1D 1.5 , 5 years 
 
 
Biological: HbA1c levels at diagnosis, 1.5 , 5 
years 
 
Psychosocial: Ethnicity (non- white) 
 
Environmental: Diagnostic era ( pre 2000, 
2000-03, 2004-09)  
 
 
Health services:  Insulin therapy 
Association with 
HbA1c levels 
Regression, 
stratified 
analyses 
++ progressively increased 
in all age groups, highest 
in >10 year olds 
 
++   
 
 
++ in children > 5 years 
old 
 
++ progressively increased 
at diagnosis and f/u 
 
++ at all-time points 
 
++ high levels in pre 2004-
2009 group at diagnosis, 
1.5 and 5 years  
 
++ HbA1c levels high at 
diagnosis and rose 
High (5). 
5 different 
methods used 
to analyse 
HbA1c during 
the study 
period 
 
 
 
 
 
 
 
 
 
 
 significantly at f/u 
3 Hanberger 
2014 (32) 
 
Sweden 
Prospective 
Cohort 
REP: 8020 children 
(4430 males), with 
type 1 diabetes, 
who were 
registered in 
SWEDIABKIDS 
registry in Sweden 
between 2000 and 
2010 
0-18 years  0-3 years Biological:  Age (0-14 years) at diagnosis and 3 
year f/u 
 
 
Biological: Gender female at diagnosis and f/u 
 
 
Biological: HbA1c levels at diagnosis and at 
f/u 
 
 
Environmental: Monthly/seasonal variation at 
diagnosis and at f/u 
Impact of age and 
gender on 
variations in 
HbA1c levels in 
paediatric T1D at 
onset and at f/u 
 
 
 
 
 
 
 
 
ANOVA, 
mean (SD) 
+ at diagnosis and f/u. 
Statistical significance not 
reported 
 
++ at diagnosis and f/u. 
 
 
++ predictors of HbA1c at 
3 year f/u 
 
++ Mean HbA1c at 
diagnosis was significantly 
highest in May (11%, 97 
mmol/mol) and lowest in 
(October 10.3%, 87 
mmol/mol).  
 
/ at f/u 
High (5)  
Did not 
include 
adjusted/mult
ivariate 
analysis 
4a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Redondo 
2014 (25) 
 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prospective 
cohort 
 
Paediatric 
Diabetes 
Consortium 
(PDC) T1D 
New Onset 
(NeOn) study 
REP: 857 
participants (49% 
males), 66% non-
Hispanic white and 
68% with private 
health insurance 
were recruited 
between 2009 and 
2011 in seven 
centres across USA. 
 
 
  
0-19 years 
 
Mean age 
9.1 ±4.1 
years 
1 year Health services: Clinic site with less 
therapeutic approaches 
 
Health services: fewer visits to diabetes clinic 
(range 1-6/year) 
 
Health services: Insulin dose ≥0.8/kg/day 
 
 
Health services: Daily self-monitored blood 
glucose tests >4/day 
 
Psychosocial: Ethnicity non-white 
 
 
Psychosocial: non-private health insurance  
 
 
Psychosocial: Lower household income 
 
 
Psychosocial: Lower parent education level 
 
 
Psychosocial: Not living with both parents  
 
 
Association with 
HbA1c at diagnosis 
Univariate 
and 
multivariat
e analyses 
++ at baseline and f/u 
 
 
+ at f/u 
 
 
++ at f/u 
 
 
- - at f/u 
 
 
++ at baseline and f/u 
 
 
++ at baseline and f/u 
 
 
+ + at baseline   
 
 
++ at baseline  
 
 
++ at baseline and f/u 
 
 
High (5). 
Analysis of 
clinic level 
factors 
unclear 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cengiz 2014  
(26) 
 
USA 
Biological: DKA at diagnosis 
 
Biological: Lower age <12 years at diagnosis 
 
Biological: Gender  female 
 
Biological: Tanner stage 
 
Biological: higher BMI 
 
Biological: higher positive anti-islet 
autoantibodies (GADA,IAA, IA-2) 
 
Biological: higher HbA1c at diagnosis 
 
Biological: Duration of T1D at diagnosis, 3, 6, 
9 and 12 months 
 
/ at f/u 
 
/ at f/u 
 
/ at f/u 
 
/ at f/u 
 
/ at f/u 
 
/ at f/u 
 
 
/ at f/u 
 
+ at diagnosis but – at 
other time points. 
Significance not reported. 
5 Davis 2012 
(41) 
 
UK 
Prospective 
cohort 
REP: 30 children (18 
males) within 1 
week of diagnoses 
of T1D and N=14 (8 
males) controls (age 
and sex matched 
siblings/friends) I 
paediatric clinic. 
Pre-pubertal: N=19 
Pubertal: N=8 
Post pubertal: N=3 
0-18 years 
 
Mean: 10.5 
(2.9) 
6 weeks 
and 1 year 
Biological: Gender female 
 
 
Biological:  Higher BMI / increased body fat 
 
 
Association with  
HbA1c levels at 
diagnosis and at 1 
year f/u 
Mean (SD)  
 
 
++   
 
 
++ 
Intermediate 
(3)  
Small sample 
size, 
inadequate 
analysis and 
exposure of  
outcomes  
 
  
6 Cutfield 
2011 (39) 
 
New Zealand 
Prospective 
cohort 
REP: 229 children 
(52% males) 
diagnosed with T1D 
between 2000 and 
2008 and in 
Starbase registry. 
0-15 years At 6 
month 
and at 24 
months 
Biological: Age at diagnosis <10 years old 
 
Biological: Gender female 
 
 
Biological: BMI high 
 
Biological: T1D in family 
 
 
 
Biological: HbA1c levels at 6months 
 
 
Psychosocial: Ethnicity (Non- European, 
Effect of predictors 
on glycaemic 
control at 6 
months and 24 
months after 
diagnosis 
Univariate 
analysis  
++  (6months) 
 
++ worst control at 6 
months  
 
++ (24 months) 
 
++ worse control in 
children with First degree 
relative with T1D (6 
months) 
 
++ predictors of HbA1c at 
24 months f/u 
 
++  (6 months) 
High (5) not 
adjusted/mult
ivariate 
analysis   
 Maori, Pacific islanders) 
 
Psychosocial: SES low 
 
Psychosocial: Child not living with both 
biological parents 
 
 
++  (6 months) 
 
++  ( 24 months) 
7 Giordano 
2011 (42) 
 
Italy 
Prospective 
cohort 
REP: 251 children 
(59% males) with 
T1D from Sicily, 
who were 
hospitalised 
between 1991 and 
2005 were 
recruited and 
prospectively 
followed if T1D 
treatment naïve. 
0-23 years 
 
Mean age 
15.2 ±2.8 
years 
1 and >10 
years 
Biological:  Age at diagnosis 0 - 15 
 
 
Biological: Higher HbA1c at diagnosis 
 
 
 
Biological:  T1D duration 1, 10  years 
Association with 
HbA1c levels 
Mean (SD), 
Univariate 
ANOVA 
+  
 
 
+ at 1 year f/u but ++ 
HbA1c levels higher in 
children < 15 years old 
 
++ 
Intermediate 
(4) 
inadequate 
analysis and 
measure of 
outcome/exp
osure 
8 Viswanathan 
2011 (43) 
 
USA 
 
Retrospective 
Cohort 
NON REP: 120 
children (44% 
male), Ethnicity: 
92% Caucasian, 
6.7% African-
American), 
hospitalised in 2003 
at the tertiary care 
centre at Riley 
Hospital for 
Children with Type 
1 diabetes and in 
paediatrics 
database. 
1-17 years 
 
Mean age 
7.6 ±3.9 
years 
6 weeks, 
1, 2, 3 and 
4 years 
Biological:  Age at diagnosis 0 - 17 
 
 
Biological: Duration of T1D 
 
 
 
Biological: BMI low 
 
Health Services: ICU patients versus general 
paediatric floor patients at diagnosis 
 
Biological: Acidosis (serum bicarbonate) at 
diagnosis 
 
Biological: Gender female 
 
Health services: Pump therapy 
 
Psychosocial: health insurance 
 
Association with 
HbA1c levels 
Mean (SD), 
correlation 
++ HbA1c levels increased 
with age 
 
++ at diagnosis, / at 1 and 
2 years, ++ at 3 years and 
+ at 4 year f/u  
 
++ 
 
/ 
 
 
/ 
 
 
/ 
 
- - 
 
/  
Intermediate 
(4) non 
representativ
e population, 
inadequate 
study design 
and analysis  
9 Mortensen 
2010 (40) 
 
Multinationa
l (Europe 
and Japan) 
Prospective 
cohort 
 
Hvidoere 
Remission 
Phase Study 
NON REP: 275 
children (48% 
males, 84% White 
caucasian) 
diagnosed with T1D 
between 1999 and 
2000, from 18 
0-17 years 
 
Range: 0.2-
16.8 years 
 
Mean: 9.1 
years  
Monthly 
for 12 
months  
from 
diagnosis 
Biological: Age at diagnosis  
 
 
 
 
 
Biological: Duration of T1D > 3 months 
Association with  
HbA1c levels  
Mean 
(SD),one 
way 
analysis of 
variance  
and 
multiple 
++ Significantly higher in ≥ 
10 year olds compared to 
5-9.9 year olds at 
diagnosis, 9 and 12 
months. 
 
++ HbA1c levels dropped 
High (5) 
Mainly in 
white 
Caucasians 
 centres 
representing 15 
countries in Europe 
and Japan. 
 
 
 
 
 
Biological: HbA1c levels at diagnosis 
 
 
Biological: Presence of antibodies Glutamic 
acid decarboxylase antibodies (GADA),  Islet 
cell antibodies (ICA) , insulin antibodies (IA)   
 
 
Biological: Gender 
 
Biological: Standard bicarbonate 
 
Biological: BMI 
 
Biological: C peptide  
 
Psychosocial: Ethnicity (non-white 
Caucasians) 
regression 
(at 12 
months) 
significantly at 3 months 
and then gradually 
increased across all age 
groups. 
 
++ predictors of HbA1c at 
12 months 
 
++ presence of GADA 
predictor of HbA1c at 12 
months 
+ presence of ICA and IA 
 
/ at 12 months 
 
/ at 12 months 
 
/ at 12 months 
 
/ at 12 months 
 
++ at 12 months 
10 Beck 2009 
(44) 
 
USA 
Retrospective 
cohort 
REP: 105 newly 
diagnosed children 
(69% with private 
insurance), 
managed with 
intensive insulin (>4 
inj/day): n=51 (59% 
male) or 
conventional insulin 
(<3 inj/day), n=54 
(46% male) were 
retrospectively 
identified from an 
outpatient 
academic paediatric 
endocrinology 
practice. 
0-18 years 12, 15 and 
18 
months 
Biological: Duration of T1D (12, 15 and 18 
months) 
 
 
 
 
 
Health services: Conventional insulin regimen 
(ref: intensive) 
 
 
 
 
Health services: Health Insurance (ref: 
Private) 
 
Association with 
HbA1c levels 
percentage 
(SEM), 
ANOVA 
 
 
 
 
ANOVA 
 
 
 
 
 
Chi-square 
analysis 
++ The overall HbA1c 
mean was significantly 
higher (ANOVA) in both 
groups  especially 
conventional treatment 
group 
 
++ The overall HbA1c 
mean at diagnosis (post 
hoc analysis), 12, 15, and 
18 month was significantly 
higher (ANOVA) 
 
++ The overall HbA1c 
mean significantly higher 
at diagnosis, 12, 15, and 
18 months in conventional 
treatment group (Chi-
square analysis). However, 
69 vs. 48% participants 
had private insurance and 
intensive insulin 
treatment. 
Intermediate 
(3) population 
(84% 
Caucasian), 
retrospective 
study design,  
inadequate 
analysis 
 11 Hochhauser 
2008 (45) 
 
USA 
Retrospective 
cohort 
REP: 59 children 
diagnosed with T1D 
between 1992 and 
2005 at the Division 
of pediatric 
endocrinology and 
diabetes at Mount 
Sinai medical 
centre. 
0-19 years Every 6 
months 
after 
diagnosis 
for 3 
years 
Biological: Age at diagnosis 
 
 
 
 
Biological: Gender female 
Effect on HbA1c 
levels at diagnosis, 
6, 12, 24 and 36 
months post 
diagnosis 
Analyses of 
variance 
++ Levels at diagnosis 
higher in children aged 
13+ 
/ at other time points 
 
+ girls generally had 
higher levels but those 
aged 6-12 years had 
higher levels of HbA1c 
levels at diagnosis 
Intermediate 
(4). 
Retrospective 
study design, 
baseline 
characteristics 
do not 
indicate which 
patients were  
included in 
longitudinal 
analyses. 
12 Frey 2007 
(46) 
 
USA 
Prospective 
cohort of a 
convenience 
sample 
NON REP: 71 
children (49% 
male), Ethnicity: 
51% White, 49% 
African-American), 
with T1D, recruited 
from a university 
affiliated teaching 
hospital in a major 
Midwestern city in 
USA 
7-19years 
 
Mean age 
12.8 ±2.9 
years 
At 1, 2 
and 5 
years 
Psychosocial: Ethnicity non white 
 
 
Psychosocial: Single parent family 
 
 
Psychosocial: Low family income 
 
Biological: Higher HbA1c at diagnosis 
 
Biological:  Age at diagnosis 7 - 19 
 
Biological:  Tanner stage 
 
Biological:  Higher BMI 
Association with 
HbA1c levels at 24 
months 
Regression 
modelling 
++  
 
 
++ at 1, 2 and 5 years 
 
 
+ 
 
++  
 
 +  
 
+ 
 
+ 
Intermediate 
(4). 
Population 
selection and  
study design 
inadequate 
13 Vollrath 
2007 (47) 
 
Switzerland 
Prospective 
cohort 
NON REP: 64 
German speaking 
children with new 
onset T1D and their 
parents were 
recruited from four 
children’s hospitals 
in Switzerland 
6-16 years At 4-6 
weeks, 6 
12 and 24 
months 
post 
diagnosis  
Biological: Duration of T1D (6 – 24 months) 
 
 
 
 
Biological: Gender female 
 
 
 
Biological: Age at diagnosis 
 
 
Psychosocial: SES 
 
 
 
 
Psychosocial: Personality characteristics of 
child influencing glycaemic control 
Effects on HbA1c 
levels at 1, 6,12 
and 24 months 
Correlation, 
T test, p 
values, 
multiple 
regression 
++ poorer glycaemic 
control with increasing 
duration of T1D (6 months 
v/s 2 years) 
 
/ no difference in HbA1c 
levels between boys and 
girls 
 
+NS correlation between 
age and HbA1c  
 
/ no difference in HbA1c 
levels between families 
from low, middle and 
upper SES 
 
- - conscientiousness  
/ agreeableness 
Intermediate 
(3). 
Non 
generalizable 
population, 
subjective 
outcome 
measures and 
analyses  
  
 
 
Psychosocial: Personality characteristics of 
parents influencing glycaemic control  
/ Extraversion 
/ Neuroticism 
 
- - agreeableness 
(mothers)  
/  conscientiousness  
/ agreeableness 
/ Extraversion 
/ Neuroticism 
14 Chase 2004 
(27) 
 
USA 
Prospective 
cohort 
REP: 552 children 
(57% males) with 
T1D from 1997 to 
2001 and registered 
at the Barbara 
Davis Center for 
Childhood Diabetes 
in Denver, CO. 
0- 18 years At month 
0, 1, 2-4, 
5-7, 8-10 
and 11-13 
Biological:  Age at diagnosis 0 – 18 
 
 
Biological: Duration of T1D 1 year 
 
 
 
Association with 
HbA1c levels 
Mean (SD) + HbA1c levels increased 
with age at diagnosis 
 
+  
Intermediate 
(3)  
Unclear 
population 
selection 
method, 
inadequate 
analyses and 
outcomes 
15 Sochett 1987 
(31) 
 
Canada 
Prospective 
cohort 
REP: 33 children 
newly diagnosed 
with T1D and 
followed up at 
Diabetes Clinic at 
the hospital for sick 
children, Toronto 
0.5-17.5 
years 
10 days, 
1, 3, 6 and 
12 
months 
after 
diagnosis 
Biological:  C Peptide 
 
Biological:  HbA1c levels  
 
Health services: Insulin dose ≥0.8/kg/day 
Association with 
HbA1c levels 
ANOVA / from 1 -12 months 
 
+ at 3 – 12 months 
 
/ from 1 -12 months 
Intermediate 
(4). 
Small sample 
size and 
inadequate 
analysis  
  
 Table S6:  Correlates of early glycaemic control in childhood onset T1D: Evidence from cross sectional studies 
REP: Representative; NON REP: Non representative; XS: cross sectional study design; BMI: Body Mass Index; SDS: Standard deviation score; DKA:  Diabetic ketoacidosis; f/u: Follow up; T1D: type 1 diabetes; ++: statistically 
significant positive correlation; + or - : statistically non- significant positive or negative correlation; /: no correlation. 
 
No Author, year 
and country 
Study design/ 
name  
Population and setting Age 
range  
Correlate Outcome Measure Association  Quality  assessment score 
(max 6) and comments 
A Akesson 2014 
(50) 
 
Sweden 
XS 
prospective 
REP: 8190 children( 4508 
males), diagnosed with T1D 
before 2011 and in 
SWEDIABKIDS registry in 
Sweden 
0-18 
years 
Biological: low pH 
 
Biological: low BMI 
SDS 
 
Biological: low blood 
pressure systole SDS 
 
Biological: low blood 
pressure diastole SDS 
 
Biological: Gender 
female 
 
Biological: Mother’s 
BMI high 
 
Biological: Father’s 
BMI high 
Association with HbA1c at 
diagnosis 
Β coefficient with 95% CI 
and p value 
++ 
 
++ 
 
 
+ 
 
 
+ 
 
 
++  
 
 
++ 
 
 
++ 
Intermediate (4)  
XS study design and 
inadequate analysis  
B Lawes 2014 
(2) 
 
 
Scotland, 
UK 
XS 
Retrospective  
NON REP: 155 children ≤ 16 
years from NHS Highland 
Paediatric diabetic services, 
North of Scotland, diagnosed 
between Jan 1993 and Aug 
2011 and receiving care 
between Nov 2008 and Aug 
2012.40% patients lived in 
remote/rural areas. 
 
 
0-16 
years 
Biological : Gender 
female 
 
Biological : Age at 
diagnosis <11 years  
 
Biological :  T1D in 
family 
 
Biological : high BMI 
SDS at diagnosis 
 
Biological : DKA at 
diagnosis 
 
Biological : Coeliac 
disease 
 
Biological : Thyroid 
association with baseline 
0-6 month from diagnosis) 
HbA1c  
Univariate, multivariate 
linear, logistic and cox 
regression models  
++  
 
 
+   
 
 
+ 
 
 
++ 
 
 
+ 
 
 
+ 
 
 
++ 
Intermediate (3)  
Retrospective XS study 
design, excluded patients 
with < 1 year f/u from 
diagnosis. Included only 
patients from North 
Scotland. 
 disease 
 
Biological : Other 
physical comorbidity 
 
Psychosocial : Most 
deprived Scottish 
Index of Multiple 
Deprivation quintile 
 
Psychosocial : Living 
with < 2 biological 
parents 
 
Psychosocial : Subject 
of child welfare 
concerns 
 
Psychosocial : 
enduring parental 
health problem 
 
Health Service: 
distance from clinic 
hub 
 
Health Service: Insulin 
regimen at 2 year f/u 
 
 
 
 
 
Environmental: living 
remotely 
 
 
- 
 
 
+ 
 
 
 
 
++ 
 
 
 
++ 
 
 
 
 
+ 
 
 
 
- 
 
 
+ for 3 to 4 doses 
per day (ref 1 
dose/day) 
 
- for 2 doses per day 
(ref 1 dose/day) 
 
- - 
 
 
 
C Samuelsson 
2014 (4) 
 
Sweden 
XS 
prospective 
NON REP: 1543 children and 
adolescents (920 males) 
from Swedish paediatric 
diabetes quality registry 
(SWEDIABKIDS) and the 
national diabetes register 
(NDR) 
Age 5-9 years: N= 89 (5.8%) 
Age 10-14 years: N= 769 
5-19 
years 
Biological: Age at 
diagnosis < 10 years 
 
Biological: Gender 
female 
 
 
Association with HbA1c 
levels at 3-15 months after 
diagnosis 
Mean, p value ++  at diagnosis and 
at f/up 
 
 
+ at diagnosis 
 
 
 
Intermediate (4) 
XS study design, non- 
representative child 
population (children < 5 
years not included and 
very few children 
diagnosed before the age 
of 10)  
 (49.8%) 
Age 15-19 years: N= 685 
(44.4%) 
Mean age at diagnosis: 13.9 
years. 
Mean duration of T1D at f/u: 
7.1 years  
Mean HbA1c adjacent to 
diagnosis: ≥70mmol/mol 
(8.6)% 
D Sammuelsson 
2013 (48) 
 
Sweden 
XS 
prospective  
 
The Better 
Diabetes 
Diagnosis 
REP: 3824 children newly 
diagnosed with T1D in 2005 
from 43 Swedish paediatric 
clinics 
0-18 
years 
Biological: age at 
diagnosis 6-15 year 
olds 
 
Biological: Gender 
female 
 
 
Effect on HbA1c  at 
diagnosis 
Mean SD ++  
 
  
 
++  
 
 
Intermediate (4). 
XS study design and 
inadequate analysis 
E Redondo 
2013 (24) 
& 2012 (49) 
 
USA 
XS 
prospective 
REP: 607 and 524 children 
respectively, aged < 19 years 
and newly diagnosed with 
T1D at Texas children’s 
hospital 
 Biological: anti-islet 
autoantibody 
expression  
 
Biological: Beta-cell 
function preservation 
with C-peptide 
<2ng/mL 
 
Biological: BMI high 
 
Psychosocial:  
Ethnicity non white 
Association with HbA1c at 
diagnosis 
Mean SD ++ 
 
 
 
++ 
 
 
 
++  
 
 
+  
 
Intermediate (4). 
XS study design and 
inadequate analysis 
 
 
 
 
